Harvest Fund Management Co. Ltd Buys 7,528 Shares of Astrazeneca Plc $AZN

Harvest Fund Management Co. Ltd increased its stake in shares of Astrazeneca Plc (NYSE:AZN) by 20.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 43,583 shares of the company’s stock after buying an additional 7,528 shares during the period. Harvest Fund Management Co. Ltd’s holdings in Astrazeneca were worth $7,649,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of AZN. Triumph Capital Management bought a new stake in shares of Astrazeneca during the 3rd quarter worth about $25,000. Bangor Savings Bank boosted its holdings in Astrazeneca by 102.7% in the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after purchasing an additional 154 shares during the period. Eagle Bay Advisors LLC bought a new stake in Astrazeneca in the 4th quarter valued at about $30,000. YANKCOM Partnership bought a new stake in Astrazeneca in the 4th quarter valued at about $31,000. Finally, TFC Financial Management Inc. boosted its holdings in Astrazeneca by 3,350.0% in the 4th quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock valued at $32,000 after purchasing an additional 335 shares during the period. Institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on AZN. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a report on Thursday, May 21st. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Weiss Ratings began coverage on shares of Astrazeneca in a report on Wednesday, March 11th. They issued a “buy (b)” rating for the company. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Finally, Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Stock Performance

Shares of Astrazeneca stock opened at $181.72 on Friday. The company has a 50 day moving average of $190.77 and a 200-day moving average of $184.71. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The company has a market cap of $281.83 billion, a PE ratio of 27.29, a price-to-earnings-growth ratio of 1.51 and a beta of 0.25.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The company had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. As a group, equities research analysts forecast that Astrazeneca Plc will post 9.52 earnings per share for the current fiscal year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.